From Ablation to Precision: How STAR & eB4T Could Transform Arrhythmia Care

The Unmet Challenge in Cardiac Arrhythmia Treatment

Millions of patients affected, limited options and a growing need for safer and more precise therapies.

Cardiac arrhythmias are among the most pressing challenges in cardiovascular medicine, responsible for 15–20% of all deaths worldwide and affecting millions of patients each year. Life-threatening forms such as atrial fibrillation, ventricular tachycardia, and ventricular arrhythmias pose particularly urgent clinical problems, with sudden cardiac death from ventricular arrhythmias remaining a leading cause of mortality.

Despite advances in therapy, treatment options for patients with refractory cardiac arrhythmias remain limited. Conventional catheter ablation can offer relief, but its reach is restricted: it cannot effectively target arrhythmogenic tissue located deep within the heart muscle. These procedures are complex, require highly specialized expertise, and carry significant procedural risks. The situation is even more challenging for patients with structural heart disease, where arrhythmogenic areas often lie in regions inaccessible to standard radiofrequency or cryoablation. High recurrence rates are common, leading to repeated interventions and growing risks over time. In addition, many patients are not suitable candidates for ablation due to comorbidities, advanced age, or previous treatment failures, leaving them with few therapeutic alternatives.

Drug therapy, though a mainstay in arrhythmia management, frequently falls short in refractory cases and introduces systemic side effects with variable efficacy. As a result, a large group of patients continues to suffer from persistent, life-threatening arrhythmias despite existing treatments. This reality highlights a critical need for non-invasive, highly precise therapies that can reach deep cardiac tissue while preserving surrounding healthy structures. The ideal approach would combine accuracy and safety, eliminating the need for general anesthesia and reducing procedural risks.

STAR: A New Frontier in Non-Invasive Cardiac Therapy

STAR treatment offers new hope where conventional ablation fails.

Stereotactic Arrhythmia Radioablation (STAR) represents a revolutionary paradigm shift in cardiac electrophysiology, emerging as a groundbreaking non-invasive alternative to traditional catheter ablation for treating refractory cardiac arrhythmias. Rather than requiring physical access to the heart, STAR delivers precisely focused, high-dose radiation to disrupt abnormal electrical pathways responsible for arrhythmia, targeting the problem from outside the body with exceptional accuracy.

The most advanced clinical use of STAR today focuses on refractory ventricular tachycardia in patients with structural heart disease. These are often complex cases where catheter ablation has failed or is considered too risky. STAR combines precision with reduced procedural risk, offering a much-needed therapeutic option for those who would otherwise have limited alternatives. Early clinical studies have produced remarkable results, showing up to a 92% reduction in ventricular tachycardia burden within six months. These outcomes are comparable to catheter ablation in efficacy while offering a superior safety profile, especially for high-risk patients. STAR’s non-invasive nature also translates to fewer complications and potentially lower treatment costs.

At the forefront of STAR development is the European STOPSTORM consortium, which has emerged as a leading force in advancing STAR technology, bringing together 31 clinical and research institutions across Europe in a coordinated effort to harmonize STAR practice and establish standardized protocols. represents a significant milestone in the development and standardization of STAR techniques, ensuring consistent quality and safety across participating centers while facilitating knowledge sharing and best practice development, and accelerating the integration of STAR into clinical practice.

The growing body of clinical evidence supporting STAR efficacy, combined with ongoing technological advancement and international collaborative efforts, positions this innovative treatment modality as a transformative approach in cardiac arrhythmia management. As the technology continues to mature and clinical experience expands, STAR is poised to become an increasingly important component of comprehensive cardiac electrophysiology care, offering hope to patients with previously limited therapeutic options.

Where STAR Still Falls Short

Technical and clinical barriers limit today’s photon-based systems from reaching full potential.

While STAR treatment has shown remarkable promise, its clinical adoption remains limited by several technical and practical challenges. Most existing STAR treatments rely on photon-based linear accelerators (LINACs) originally developed for oncology, not for the unique demands of cardiac therapy. As a result, current systems face constraints in beam precision, dose distribution, and protection of surrounding healthy tissue.

  • Precision and dose delivery: STAR demands exceptional accuracy, often within sub-millimeter precision, to target small moving cardiac regions typically only 20-50 cm³ in size. Continuous cardiac and respiratory motion complicate dose delivery, making it difficult to confine radiation strictly to arrhythmogenic tissue. Even minor inaccuracies can expose healthy myocardium or nearby organs, leading to unintended side effects.

  • Dose distribution challenges: Photon therapy inherently delivers significant entrance and exit doses, limiting its ability to treat deep-seated cardiac targets without irradiating healthy tissue. Unlike particle-based approaches, photon beams lack intrinsic steering and dose-shaping capabilities, reducing flexibility in achieving optimal dose conformity for complex cardiac anatomies. Consensus is also lacking on safe dose limits for cardiac substructures and on the degree of dose heterogeneity acceptable within target zones.

  • Protecting healthy tissue: Maintaining steep dose gradients is crucial to minimize exposure to surrounding organs. However, the irregular shape and constant motion of cardiac targets make this extremely difficult. Reported complications include radiation pneumonitis, esophageal injury, and collateral cardiac tissue damage, underscoring the importance of more precise and adaptive treatment delivery.

  • Treatment planning and imaging complexity: STAR treatment planning remains highly complex, requiring detailed anatomical mapping and advanced imaging integration (such as electroanatomical mapping with CT or MRI). Manual or semi-automated segmentation introduces variability, while the absence of standardized workflows can compromise consistency across clinical centers.

  • Motion management and treatment time: Cardiac and respiratory motion create major challenges in aligning planned and delivered doses. Current management techniques, such as gating or real-time tracking, add technological complexity and often cannot fully compensate for the heart’s dynamic movement. Extended treatment times with conventional photon systems further increase the risk of motion-related inaccuracies and reduce patient comfort.

  • Recurrence and long-term outcomes: Despite encouraging short-term results, long-term arrhythmia recurrence remains a concern, especially in complex cases or when suboptimal doses are used. Evidence suggests that durable suppression may require doses exceeding 25 Gy, which also heightens the risk of radiation-induced toxicity.

  • Limited accessibility: Finally, access to the advanced equipment and imaging infrastructure required for STAR is limited, particularly outside major academic or specialized centers. This restricts the broader adoption of STAR and highlights the need for more compact, precise, and dedicated technologies optimized for cardiac use.

Our eB4T Solution: Enabling the Next Generation of STAR Treatment

Our LPA-VHEE system brings precision, flexibility, and accessibility to cardiac radiotherapy.

The eB4T project introduces a breakthrough approach to STAR through its LPA-VHEE source, capable of delivering 200 MeV electrons with exceptional precision. Compared to conventional photon therapy, VHEE beams provide superior dose distribution, reduced sensitivity to tissue heterogeneities, and enhanced sparing of surrounding healthy tissue enabling precise dose conformity even for moving cardiac targets.

The eB4T system delivers electron beams with sub-millimeter accuracy and percent-level shot-to-shot pointing stability, ensuring exceptional targeting reliability. Moreover, its compact design allows seamless integration into existing medical infrastructure, including conventional LINAC-based and photon therapy systems. This compatibility minimizes implementation barriers and capital costs, simplifying the adoption of STAR capabilities in clinical environments.

VHEE beams can also be magnetically steered, offering unprecedented flexibility in beam delivery and real-time motion compensation. This feature enables adaptive treatment strategies that respond dynamically to cardiac motion, enhancing precision and safety. Their deep penetration and sharp beam edges further improve dose conformity while minimizing radiation exposure to organs at risk. Built on laser plasma accelerator (LPA) technology, eB4T provides a compact, reliable, and cost-effective platform for generating highly energetic electrons ideal for STAR applications. The result is a system capable of delivering highly accurate, non-invasive treatment for refractory cardiac arrhythmias with minimal collateral damage.

By combining precision, compactness, and affordability, eB4T’s technology has the potential to make STAR more accessible, facilitating progress on this novel treatment and improving accessibility across the globe.

Looking Ahead

Paving the way for safer, more accessible arrhythmia treatment worldwide.

The development of eB4T’s VHEE technology represents a transformative step toward safer, more precise, and accessible treatment for patients with refractory cardiac arrhythmias. By addressing the limitations of current STAR approaches, eB4T has the potential to expand the reach of non-invasive cardiac radioablation and improve outcomes for patients worldwide.

To learn more about our technology, clinical collaborations, or investment opportunities, contact us today and explore how eB4T is shaping the future of cardiac arrhythmia care.